Ozempic’s Maker Is Using AI to Try to Discover the Next Big Weight-Loss Drug Faster
Demand for obesity drugs has become one of the biggest stories in the pharmaceutical industry over the past year. Novo Nordisk, the Danish company behind Ozempic and Wegovy, said it is using artificial intelligence to help find new weight-loss drug candidates faster. The effort shows how major drugmakers are trying to shorten the earliest stages of research as competition in obesity care grows.
Novo Nordisk expands AI use in drug discovery
Novo Nordisk said on May 2, 2024, during its quarterly earnings call that it is using AI tools to support early-stage research for future obesity and diabetes medicines. The company said the goal is to identify promising drug targets and molecules faster than with traditional lab screening alone. Novo Nordisk has not publicly released a number for how many AI-discovered candidates are currently in its obesity pipeline.
The company confirmed that AI is being used as part of its broader research work rather than as a stand-alone product program. Novo Nordisk also said its current commercial growth is still being driven by approved medicines including Ozempic and Wegovy. Those drugs have helped make obesity treatment one of the company’s largest business priorities in 2024.
What is confirmed, and what is not yet public
Novo Nordisk’s AI work is part of its global research operation, and the company has not tied the effort to a single US state or city. What is confirmed is that the company is trying to use AI to speed up the discovery process for future medicines. What is not yet known is which specific new obesity compounds, if any, were first identified through those AI systems.
The company also has not released a full timeline for when any AI-supported obesity drug candidates could move into human trials. As of May 2024, Novo Nordisk’s public comments focused on discovery and pipeline development, not on a launch date for a new medicine. That means patients and prescribers in the US should not expect an immediate replacement for Ozempic or Wegovy based on the company’s AI work alone.
Why drugmakers are speeding up the search
Novo Nordisk’s AI push comes as demand for GLP-1 medicines remains high and competition in the obesity market keeps building. The company said in 2024 that it is investing across research, production, and pipeline expansion to meet long-term demand. AI fits into that strategy because drug discovery can take years, and earlier identification of promising compounds could help shorten part of that timeline.
The broader context is a fast-moving race among major pharmaceutical companies to develop follow-up obesity drugs that may improve weight loss, dosing, or side effects. Novo Nordisk has said it sees obesity as a chronic disease with long-term treatment demand, which is why future pipeline work matters beyond current blockbuster drugs. For patients, the immediate reality remains the same in 2024: Ozempic and Wegovy are the company’s best-known products, while the next wave is still in research.
